Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 18:8:4.
doi: 10.3389/fped.2020.00004. eCollection 2020.

Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports

Marie Hully  1   2 , Christine Barnerias  1 , Delphine Chabalier  1 , Sophie Le Guen  3 , Virginie Germa  2 , Elodie Deladriere  2 , Catherine Vanhulle  4 , Jean-Marie Cuisset  5 , Brigitte Chabrol  6 , Claude Cances  7 , Carole Vuillerot  8 , Caroline Espil  9 , Michele Mayer  10 , Marie-Christine Nougues  10 , Pascal Sabouraud  11 , Jeremie Lefranc  12 , Vincent Laugel  13 , Francois Rivier  14 , Ulrike Walther Louvier  15 , Julien Durigneux  16 , Sylvia Napuri  17 , Catherine Sarret  18 , Michel Renouil  19 , Alice Masurel  20 , Marcel-Louis Viallard  21   22 , Isabelle Desguerre  1
Affiliations

Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports

Marie Hully et al. Front Pediatr. .

Abstract

Spinal muscular atrophy type 1 (SMA-1) is a severe neurodegenerative disorder, which in the absence of curative treatment, leads to death before 1 year of age in most cases. Caring for these short-lived and severely impaired infants requires palliative management. New drugs (nusinersen) have recently been developed that may modify SMA-1 natural history and thus raise ethical concerns about the appropriate level of care for patients. The national Hospital Clinical Research Program (PHRC) called "Assessment of clinical practices of palliative care in children with Spinal Muscular Atrophy Type 1 (SMA-1)" was a multicenter prospective study conducted in France between 2012 and 2016 to report palliative practices in SMA-1 in real life through prospective caregivers' reports about their infants' management. Thirty-nine patients were included in the prospective PHRC (17 centers). We also studied retrospective data regarding management of 43 other SMA-1 patients (18 centers) over the same period, including seven treated with nusinersen, in comparison with historical data from 222 patients previously published over two periods of 10 years (1989-2009). In the latest period studied, median age at diagnosis was 3 months [0.6-10.4]. Seventy-seven patients died at a median 6 months of age[1-27]: 32% at home and 8% in an intensive care unit. Eighty-five percent of patients received enteral nutrition, some through a gastrostomy (6%). Sixteen percent had a non-invasive ventilation (NIV). Seventy-seven percent received sedative treatment at the time of death. Over time, palliative management occurred more frequently at home with increased levels of technical supportive care (enteral nutrition, oxygenotherapy, and analgesic and sedative treatments). No statistical difference was found between the prospective and retrospective patients for the last period. However, significant differences were found between patients treated with nusinersen vs. those untreated. Our data confirm that palliative care is essential in management of SMA-1 patients and that parents are extensively involved in everyday patient care. Our data suggest that nusinersen treatment was accompanied by significantly more invasive supportive care, indicating that a re-examination of standard clinical practices should explicitly consider what treatment pathways are in infants' and caregivers' best interest. This study was registered on clinicaltrials.gov under the reference NCT01862042 (https://clinicaltrials.gov/ct2/show/study/NCT01862042?cond=SMA1&rank=8).

Keywords: SMA; caregivers; ethics; palliative care; standard of care.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of the patients involved in the prospective and retrospective studies (2012–2016), as well as data from previous published French study (1989–2009).
Figure 2
Figure 2
Parents' opinion about their child's technical care.
Figure 3
Figure 3
Parents' opinion about their child's comfort.
See this image and copyright information in PMC

References

    1. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. . Identification and characterization of a spinal muscular atrophy-determining gene. Cell. (1995) 80:155–65. 10.1016/0092-8674(95)90460-3 - DOI - PubMed
    1. Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. . Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis. (2017) 12:124. 10.1186/s13023-017-0671-8 - DOI - PMC - PubMed
    1. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al. . Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. (1997) 16:265–69. 10.1038/ng0797-265 - DOI - PubMed
    1. Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. (2006) 119:422–8. 10.1007/s00439-006-0156-7 - DOI - PubMed
    1. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. . Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. (2018) 28:103–15. 10.1016/j.nmd.2017.11.005 - DOI - PubMed

Associated data